JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.8 CNY | -2.73% |
|
-1.71% | -37.46% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.
Sector
Pharmaceuticals
Calendar
05/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
17.8
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.46% | 303M | |
| -2.47% | 89.37B | |
| +2.76% | 40.65B | |
| -13.05% | 32.81B | |
| +51.46% | 25B | |
| -16.52% | 15.29B | |
| -42.60% | 11.61B | |
| -12.82% | 11.49B | |
| +5.62% | 8.98B | |
| -7.72% | 8.23B |
- Stock Market
- Equities
- 688670 Stock
- News Jiangsu Gdk Biological Technology Co., Ltd
- Jiangsu Gdk Biotechnology Forecasts Lower Profit in 2022 on COVID-19 Outbreaks